SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Orphan Drug Act
0 references·5 citing·18 second hop
Orphan Drug Act (1990)Orphan Drug ActWhy orphan drug coverage reimbursement decision-making needs patient and public involvement (2015)Why orphan drug coverage reim…The Evolving Drug Development Landscape: From Blockbusters to Niche Busters in the Orphan Drug Space (2014)The Evolving Drug Development…Trends in paediatric, neonatal, and adult cardiology publications over the past 10 years (2013)Trends in paediatric, neonata…The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs (2012)The Prevalence and Cost of Un…Orphan drugs revisited (2006)Orphan drugs revisitedAssessing the economic challenges posed by orphan drugs (2007)Pricing and reimbursement of orphan drugs: the need for more transparency (2011)Orphan drug development: an economically viable strategy for biopharma R&D (2012)Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases (2017)A Ladder Of Citizen Participation (1969)Public Participation Methods: A Framework for Evaluation (2000)A Typology of Public Engagement Mechanisms (2005)Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA (2017)Consensus and contention regarding redundant publications in clinical research: cross-sectional survey of editors and authors (2003)Relative Citation Impact of Various Study Designs in the Health Sciences (2005)Does orphan drug legislation really answer the needs of patients? (2008)Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics (2009)The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? (2009)The Orphan Drug Act (2015)Setting Health Care Priorities in Oregon (1991)Drugs for exceptionally rare diseases: do they deserve special status for funding? (2005)Orphan drugs and the NHS: should we value rarity? (2005)Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe (2010)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2006Orphan drugs revisited60 cited
  • 2014The Evolving Drug Development Landscape: From Blockbusters to Niche Busters in the Orphan Drug Space57 cited
  • 2012The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs51 cited
  • 2015Why orphan drug coverage reimbursement decision-making needs patient and public involvement48 cited
  • 2013Trends in paediatric, neonatal, and adult cardiology publications over the past 10 years5 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work